(Bloomberg) Novo Nordisk A/S became the second-ever European company to pass $500 billion in market value, bolstered by an upbeat outlook for its blockbuster obesity drug.Most Read from BloombergMusk’s $55 Billion Pay Package Voided, Threatening World’s Biggest FortuneByron Allen Makes $14 Billion Offer for Paramount GlobalMicrosoft Sales Top Estimates; Cloud Growth Disappoints SomeMusk Says First Neuralink Patient Received Implant in BrainMusk Judge Says ‘Unfathomable’ Deal Made Tesla CEO Ov
GlucoRedi is a new and best medicine for diabetes introduced in the market with potential benefits and it is one of the best type-2 diabetes medications.